Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats

Hypertension

Volumn 31, Issue 1, 1998, Pages 451-458

  Rocha, Ricardo ^a   Chander, Praveen N ^a   Khanna, Kavita ^a   Zuckerman, Andrea ^a   Stier, Charles T ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; MINERALOCORTICOID RECEPTOR; POTASSIUM; SODIUM; SPIRONOLACTONE; ALDOSTERONE; MINERALOCORTICOID; POTASSIUM ION; SODIUM ION;

AGING; ANIMAL; ARTICLE; BODY WEIGHT; BRAIN; CEREBROVASCULAR DISEASE; DELAYED RELEASE FORMULATION; DIURESIS; DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEINURIA; RAT; SODIUM INTAKE; SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL RATE; SYSTOLE; URINE; ALDOSTERONE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD VESSEL INJURY; CONTROLLED STUDY; HISTOPATHOLOGY; HYPERTENSION; KALIURESIS; KIDNEY; MALE; NATRIURESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION;

AGING; ALDOSTERONE ANTAGONISTS; ANIMALS; BODY WEIGHT; BRAIN; CEREBROVASCULAR DISORDERS; DELAYED-ACTION PREPARATIONS; DIURESIS; POTASSIUM; PROTEINURIA; RATS; RATS, INBRED SHR; RECEPTORS, MINERALOCORTICOID; SODIUM; SODIUM, DIETARY; SPIRONOLACTONE; SURVIVAL RATE; SYSTOLE;

EID: 0031600240     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.31.1.451     Document Type: Article

References (41)

1. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441-449.
2. Stier CT Jr, Benter IF, Ahmad S, Zuo H, Selig N, Roethel S, Levine S, Itskovitz HD. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension. 1989;13:115-121.
3. Stier CT Jr, Chander PN, Gutstein WH, Levine S, Itskovitz HD. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens. 1991;4:680-687.
4. Stier CT Jr, Mahboubi K, DiPippo VA, Levine S, Chander PN. The antiproteinuric action of enalapril in stroke-prone spontaneously hypertensive rats is unrelated to alterations in urinary prostaglandins. J Pharmacol Exp Ther. 1992;260:1410-1415.
5. Ogiku N, Sumikawa H, Hashimoto Y, Ishida R. Prophylactic effect of imidapril on stroke in stroke-prone spontaneously hypertensive rats. Stroke. 1993;24:245-252.
6. Vacher E, Fornes P, Domergue V, Richer C, Bruneval P, Giudicelli J-F. Quinapril prevents stroke both during and after the treatment period in stroke-prone spontaneously hypertensive rats. Am J Hypertens. 1993;6:951-959.
7. Stier CT Jr, Sim GJ, Mahboubi K, Shen W, Levine S, Chander PN. Prevention of stroke and hypertensive renal disease by the angiotensin II receptor antagonist DuP 753 in salt-loaded stroke-prone SHR. In: Current Advances in ACE Inhibition 2, ed. by GA MacGregor and PS Sever, Churchill Livingstone, London, 1991;252-256.
8. Stier CT Jr, Adler LA, Levine S, Chander PN. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens. 1993;11:S37-S42.
9. Camargo MJF, von Lutterotti N, Campbell WG Jr, Pecker MS, James GD, Timmermans PB, Laragh JH. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockage. J Hypertens. 1993;11:31-40.
10. Shibota M, Nagaoka A, Shino A, Fujita T. Renin-angiotensin system in stroke-prone spontaneously hypertensive rats. Am J Physiol. 1979;5:H409-H416.
11. Quinn MJF, Williams GH. Regulation of aldosterone secretion. Ann Rev Physiol. 1988;50:409-426.
12. Foster RH, MacFarlane CH, Bustamante MO. Recent progress in understanding aldosterone secretion. Gen Pharmacol. 1997;28:647-651.
13. Selye H, Hall CE, Rowley EM. Malignant hypertension produced by treatment with desoxycorticosterone acetate and sodium chloride. Can Med Assoc J. 1943;49:88-92.
14. Robert, A. Complete prevention of cerebral accidents in malignant hypertension. Circ Res. 1956;4:527-532.
15. Gavras H, Brunner HR, Laragh JH, Vaughan ED Jr, Koss M, Cote LJ, Gavras I. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess. Role of renin and sodium in vascular changes. Circ Res. 1975;36:300-309.
16. Mistry M, Muirhead EE, Yamaguchi Y, Nasjletti A. Renal function in rats with angiotensin II-salt-induced hypertension: Effect of thromboxane synthesis inhibition and receptor blockade. J Hypertens. 1990;8:75-83.
17. Nagaoka A, Shino A, Iwatsuka H. Accelerating effects of dexamethasone and thyroxine on hypertension without accompanying stroke in stroke-prone spontaneously hypertensive rats. Life Sci. 1979;24:71-78.
18. Ogata J, Fujishima M, Tamaki K, Nakatomi Y, Ishitsuka T, Omae T. Stroke-prone spontaneously hypertensive rats as an experimental model of malignant hypertension. A pathological study. Virchows Arch [Pathol Anat]. 1982;394:185-194.
19. Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res. 1974;34&35:I-143-I-153.
20. deGasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J, Wieland P, Wehrli HU. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650-656.
21. 2 receptor antagonist, in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens. 1996;18:171-188.
22. MacLeod AB, Vasdev S, Smeda JS. The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril-treated hypertensive rats. Stroke. 1997;28:1821-1829.
23. Dworkin LD, Levin RI, Benstein JA, Parker M, Ullian ME, Kim Y, Feiner HD. Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol. 1990;259:F598-F604.
24. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063-1068.
25. Rocha R., Khanna K, Burstein J, Cho J, Zuckerman A, Chander PN, and Stier CT, Jr. Aldosterone reverses the renal protective effect of ACE inhibition in stroke-prone hypertensive rats. J Am Soc Nephrol. 1997;8:A1407. (Abstract).
26. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1995;32:E657-E662.
27. Gomez-Sanchez EP. Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology. 1986;118:819-823.
28. Gomez-Sanchez EP. What is the role of the central nervous system in mineralocorticoid hypertension? Am J Hypertens. 1991;4:374-381.
29. Chabert PR, Guelpa-Decorzant C, Riondel AM, Vallotton MB. Effect of spironolactone on electrolytes, renin, ACTH and corticosteroids in the rat. J Steroid Biochem. 1984;6A:1253-1259.
30. Smeda JS, Tkachenko O. Effects of diuretics on stroke development in Kyoto-Wistar stroke-prone spontaneously hypertensive rats. Clin Sci. 1991;81:335-340.
31. Tobian L, Lange J, Ulm K, Wold L, Iwai J. Potassium reduces cerebral hemorrhage and death rate in hypertensive rats even when blood pressure is not lowered. Hypertension. 1985;7(suppl II):110-114.
32. Volpe M, Camargo MJF, Mueller FB, Campbell WG Jr, Sealey JE, Pecker MS, Sosa RE, Laragh JH Relation of plasma renin to end organ damage and to protection of K + feeding in stroke-prone hypertensive rats. Hypertension. 1990;15:318-326.
33. Ishimitsu T, Tobian L, Sugimoto K, Lange JM. High potassium diets reduce macrophage adherence to the vascular wall in stroke-prone spontaneously hypertensive rats. J Vasc Res. 1995;32:406-412.
34. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;71:12A-16A.
35. Nicoletti A, Heudes D, Hinglais N, Appay M-D, Philippe M, Sassy-Prigent C, Bariety J, Michel J-P. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension. 1995;26:101-111.
36. Funder JW. Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens. 1997;19:885-899.
37. Christ M, Meyer C, Sippel K, Wehling M. Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun. 1995;213:123-129.
38. Lynch JJ, Ferro TJ, Blumenstock AM, Malik AB. Increased endothelial albumin permeability mediated by protein kinase C activation. J Clin Invest. 1990;85:1991-1998.
39. Hempel A, Maach C, Heintze U, Lindschau C, Dietz R, Luft FC, Haller H. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res. 1997;81363-371:.
40. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension. 1992;20:67-73.
41. Masson GMC, Mikasa A, Yasuda H. Experimental vascular disease elicited by aldosterone and renin. Endocrinology. 1962;71:505-512.